


**Supplementary Figure 1.** LPS inhibited cell viability and increase IL-1β, IL-18, and SNHG16 levels in a dose-dependent manner. BEAS-2B cells were treated with 0.1, 1, or 10 μg/ml LPS for 24 h. **A)** Cell viability was tested through CCK-8 assay. **B)** IL-18 and IL-1β levels in supernatants of BEAS-2B cells were examined via ELISA. **C)** SNHG16 levels in BEAS-2B cells were determined by RT-qPCR. BEAS-2B cells were treated with LPS, LPS + si-NC, or LPS + si-SNHG16. *n* = 3 per group. \*\**p* < 0.01, \*\*\**p* < 0.001



**Supplementary Figure 2.** The effect of LPS on the levels of different miRNAs. BEAS-2B cells were treated with LPS (1 μg/ml) for 24 h. The expression of miR-339-5p, miR-485-5p, miR-520a-5p, miR-525-5p, miR-641, and miR-193a-5p in BEAS-2B cells was investigated by RT-qPCR. *n* = 3 per group. \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001